The world is on the cusp of an epidemic of dementia, a condition in which memory and cognition decline in the elderly.
That’s caused by the accumulation of plaques, the memory-wasting proteins that accumulate in the brain and eventually cause the cognitive decline.
The drug treatment, called AMPH-10, could help patients recover and possibly save lives.
The treatment works by targeting amyloid beta, which causes the buildup of a protein that is found in Alzheimer’s disease.AMPH-20, the first FDA-approved drug approved for Alzheimer’s, also works by blocking amyloids, a protein found in amylopectin, another protein in amlodipine, a drug that has been approved for treating Alzheimer’s.
The treatment can reverse the Alzheimer’s-related decline, said Dr. David J. Mazzoni, a neurologist at Stanford University and the first director of the Alzheimer Disease Center at Stanford Medical Center.
In Alzheimer’s patients, the Alzheimer disease plaque is called amylofibril, and it is found on the surface of amylotrophic protein, the main protein found inside cells.
That protein binds to the proteins inside the amylocytoplasm, a membrane that surrounds the cell’s cell membrane.
The protein binds tightly to the amlocytophelium, preventing it from forming a protective coating.
Without that protective coating, the amacrine protein inside the cell could get into the cell and cause cell damage.
In amylo-deficient patients, amylophosphatidylcholine (AMP), a neurotransmitter that’s produced by neurons, is not made.
That means that amylosomes cannot bind AMP to prevent the buildup.
In patients with amylolysis, aminosomes that are made in the amylethyl group of the amine-containing protein, amine A, do not bind AMPs to prevent amylosis.
In these patients, AMPH treatment can also cause amylous sclerosis, a progressive loss of function of neurons in the central nervous system.AMP treatment is currently approved in humans for treating mild cognitive impairment, and its use in dementia is currently limited.
Researchers have shown that it can reverse amylotic decline and may be more effective than traditional therapies for patients with Alzheimer’s but not dementia.
The FDA approved AMPH 10 in June for use in patients over the age of 60 with mild cognitive impairments.
The Drug Enforcement Administration approved AMP for use to treat people over the same age group as Alzheimer’s in March.
The company plans to begin clinical trials of AMPH on healthy people in the United States and the United Kingdom later this year.
It will be available for prescription in the U.S. and Europe in 2017, and could be available in Canada and Australia in 2018.